Literature DB >> 12634940

Expression of the apoptosis accelerator Bax in rheumatoid arthritis synovium.

Insa Hilbers1, Torsten Hansen, Peter K Petrow, Andreas Gaumann, Rolf Bräuer, Günther Salzmann, Renate E Gay, Hartwig Kosmehl, C James Kirkpatrick, Steffen Gay, Jörg Kriegsmann.   

Abstract

OBJECTIVE: The aim of this study was to analyze the expression of apoptosis-related molecules in rheumatoid arthritis (RA) synovium, with special emphasis on the apoptosis accelerator Bax.
METHODS: Immunohistochemical analysis of Bax, Bcl-2, and Bcl-x(L) was performed in tissue specimens of patients with RA and compared to normal synovial tissue. Expression of Bax was additionally determined by double labeling with CD68, p53, and Ki-67 (clone MIB-1). Apoptotic cells were further identified by the terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling (TUNEL) method.
RESULTS: In RA, expression of Bax was higher than in healthy controls and occurred in CD68-positive and -negative synoviocytes. Strong Bax staining was also found in chondrocytes at sites of cartilage degradation. Bax-positive synoviocytes could be detected with p53 and also with Ki-67. Bax and Bcl-x(L) were markedly colocalized in synovium. The TUNEL method revealed only few positive synoviocytes.
CONCLUSIONS: The marked colocalization of Bax and antiapoptotic Bcl-x(L) as well as the low frequency of TUNEL-positive cells in RA synovium suggest that Bax activity is not sufficient to decrease synovial hyperplasia in RA. Apoptotic mechanisms in RA chondrocytes might also be important for the pathogenesis of joint damage.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12634940     DOI: 10.1007/s00296-002-0255-2

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  6 in total

1.  Bim-Bcl-2 homology 3 mimetic therapy is effective at suppressing inflammatory arthritis through the activation of myeloid cell apoptosis.

Authors:  John C Scatizzi; Jack Hutcheson; Richard M Pope; Gary S Firestein; Alisa E Koch; Melissa Mavers; Avraham Smason; Hemant Agrawal; G Kenneth Haines; Navdeep S Chandel; Richard S Hotchkiss; Harris Perlman
Journal:  Arthritis Rheum       Date:  2010-02

2.  Bcl-x(L) expression in vivo in rheumatoid synovium.

Authors:  S Busteed; M W Bennett; C Molloy; A Houston; M A Stone; F Shanahan; M G Molloy; J O'Connell
Journal:  Clin Rheumatol       Date:  2006-03-30       Impact factor: 2.980

Review 3.  BH3-only proteins in rheumatoid arthritis: potential targets for therapeutic intervention.

Authors:  J Hutcheson; H Perlman
Journal:  Oncogene       Date:  2008-12       Impact factor: 9.867

Review 4.  The inflammatory role of phagocyte apoptotic pathways in rheumatic diseases.

Authors:  Carla M Cuda; Richard M Pope; Harris Perlman
Journal:  Nat Rev Rheumatol       Date:  2016-08-23       Impact factor: 20.543

5.  Ablation of the pro-apoptotic protein Bax protects mice from glucocorticoid-induced bone growth impairment.

Authors:  Farasat Zaman; Dionisios Chrysis; Kirsten Huntjens; Bengt Fadeel; Lars Sävendahl
Journal:  PLoS One       Date:  2012-03-19       Impact factor: 3.240

6.  Pro-apoptotic Bid is required for the resolution of the effector phase of inflammatory arthritis.

Authors:  John C Scatizzi; Jack Hutcheson; Emily Bickel; G Kenneth Haines; Harris Perlman
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.